KR20190032436A - 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 - Google Patents
폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 Download PDFInfo
- Publication number
- KR20190032436A KR20190032436A KR1020197004681A KR20197004681A KR20190032436A KR 20190032436 A KR20190032436 A KR 20190032436A KR 1020197004681 A KR1020197004681 A KR 1020197004681A KR 20197004681 A KR20197004681 A KR 20197004681A KR 20190032436 A KR20190032436 A KR 20190032436A
- Authority
- KR
- South Korea
- Prior art keywords
- weeks
- subject
- treatment
- months
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365017P | 2016-07-21 | 2016-07-21 | |
| US62/365,017 | 2016-07-21 | ||
| PCT/IB2017/054360 WO2018015897A1 (en) | 2016-07-21 | 2017-07-19 | Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190032436A true KR20190032436A (ko) | 2019-03-27 |
Family
ID=59683618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197004681A Ceased KR20190032436A (ko) | 2016-07-21 | 2017-07-19 | 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210292404A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3487584A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019521161A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190032436A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017298656A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3031346A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018015897A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202400340D0 (en) | 2024-01-10 | 2024-02-21 | Wotherspoon Hugh Robert | IL-1B binding antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US10000565B2 (en) * | 2012-11-16 | 2018-06-19 | Novartis Ag | Use of IL-1 β binding antibodies for treating peripheral arterial disease |
-
2017
- 2017-07-19 EP EP17755243.7A patent/EP3487584A1/en not_active Withdrawn
- 2017-07-19 AU AU2017298656A patent/AU2017298656A1/en not_active Abandoned
- 2017-07-19 KR KR1020197004681A patent/KR20190032436A/ko not_active Ceased
- 2017-07-19 JP JP2019502560A patent/JP2019521161A/ja active Pending
- 2017-07-19 US US16/319,630 patent/US20210292404A1/en not_active Abandoned
- 2017-07-19 CA CA3031346A patent/CA3031346A1/en not_active Abandoned
- 2017-07-19 WO PCT/IB2017/054360 patent/WO2018015897A1/en not_active Ceased
-
2020
- 2020-07-20 AU AU2020207771A patent/AU2020207771A1/en not_active Abandoned
-
2022
- 2022-02-18 US US17/675,488 patent/US20220177570A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017298656A1 (en) | 2019-02-07 |
| US20220177570A1 (en) | 2022-06-09 |
| EP3487584A1 (en) | 2019-05-29 |
| WO2018015897A1 (en) | 2018-01-25 |
| AU2017298656A2 (en) | 2019-03-28 |
| US20210292404A1 (en) | 2021-09-23 |
| CA3031346A1 (en) | 2018-01-25 |
| AU2020207771A1 (en) | 2020-08-06 |
| JP2019521161A (ja) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lukey et al. | A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis | |
| Kim et al. | Quality matters as much as quantity of skeletal muscle: clinical implications of myosteatosis in cardiometabolic health | |
| Burgel | The role of small airways in obstructive airway diseases | |
| Lim et al. | Assessment of coronary flow reserve with transthoracic Doppler echocardiography: comparison among adenosine, standard-dose dipyridamole, and high-dose dipyridamole | |
| Chen et al. | Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography | |
| Casu et al. | Can changes in renal function predict variations in β-lactam concentrations in septic patients? | |
| Dayton et al. | Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies | |
| Farahi et al. | In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients | |
| Santer et al. | Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial | |
| EP2844291B1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
| Ohar et al. | Diffusing capacity decreases after heart transplantation | |
| Chen et al. | [18F] fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation | |
| Washko et al. | Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE | |
| Camilo et al. | Pulmonary function testing and chest tomography in patients with acromegaly | |
| Gibson et al. | Ventilation heterogeneity is a treatable trait in severe asthma | |
| US20220177570A1 (en) | Use of the il-1beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis | |
| von Haehling et al. | Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial | |
| Ward et al. | Interstitial lung disease: An approach to diagnosis and management | |
| Keppler-Noreuil et al. | Phenotypic features of cystic lung disease in proteus syndrome: a clinical trial | |
| Villalobos et al. | Exploring the efficacy of benralizumab in chronic eosinophilic pneumonia following corticosteroid therapeutic failure: a case report | |
| WO2022061812A1 (zh) | 醋酸格拉替雷在制备Aβ42毒性抑制剂和清除剂中的应用 | |
| Fragni | Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model | |
| Kerget et al. | Evaluation of the Relationship between FeNO and Clinical Risk Stratification for Early Mortality in Pulmonary Embolism. | |
| RU2386397C1 (ru) | Способ диагностики функциональных изменений у больных с цервикальной дистонией | |
| Okudan et al. | Detection of alveolar epithelial injury by Tc-99m DTPA radioaerosol inhalation lung scan in rheumatoid arthritis patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190218 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200716 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220511 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20220718 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20220511 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |